Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.64 |
| ▸ | DRD3 | P35462 | 2/20 | 0.64 |
| ▸ | PRKACA | P17612 | 1/20 | 0.62 |
| ▸ | PRKACG | P22612 | 1/20 | 0.62 |
| ▸ | PRKACB | P22694 | 1/20 | 0.62 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14745935 | 0.86 | DRD2 (0.54) | DRD2DRD3PRKACAPRKACGPRKACB | |
| SCHEMBL31332598 | 0.82 | DRD2 (0.51) | DRD2DRD3PRKACAPRKACGPRKACB | |
| SCHEMBL7879783 | 0.81 | DRD2 (0.50) | DRD2DRD3 | |
| SCHEMBL136333 | 0.81 | DRD2 (0.50) | DRD2DRD3 | |
| SCHEMBL16057462 | 0.80 | DRD2 (0.69) | DRD2DRD3PRKACAPRKACGPRKACB | |
| Hydrochloric Acid SCHEMBL29564721 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL966629 | 0.80 | — | — | |
| SCHEMBL6540021 | 0.79 | DRD2 (0.50) | DRD2DRD3 | |
| SCHEMBL16412900 | 0.79 | DRD2 (0.50) | DRD2DRD3 | |
| SCHEMBL29813085 | 0.79 | DRD2 (0.50) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239756-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239756-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-07-18 | — | — | US | disclosed |
| EP-3831812-B1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | MITSUBISHI TANABE PHARMA CORP (JP) | 2023-05-10 | — | — | EP | disclosed |
| EP-3831812-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | Mitsubishi Tanabe Pharma Corporation (JP) | 2021-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239756-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | ENPP2, SSB, PLPBP | DRD2 4540/4885DRD3 4063/4885PRKACA 2782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.